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Background: Hypoadiponectinemia in lipoatrophy may be related to worsening of hypertension in stroke-prone
spontaneously hypertensive rats (SHRSP). One of the beneficial effects of candesartan (Angiotensin II Type 1
receptor blocker) for preventing hypertension may be increasing of adiponectin due to improvement of adipocyte
dysfunction. In this study, we determined the effects of candesartan or adiponectin on pathophysiologic features
and adipocyte dysfunction in SHRSP.
Methods: Candesartan was administered to male SHRSP from 16 to 20 weeks of age (2 mg/kg/day). Adiponectin
was cloned and intravenously administered to male SHRSP from 16 to 20 weeks of age. We examined biological
parameters, as well as the expression and release of adipokines.
Results: The SHRSP exhibited severe atrophy of visceral fat and progression of severe hypertension. The expression
and release of leptin and adiponectin were impaired at 6 and 20 weeks of age. Candesartan suppressed the
development of lipoatrophy and reduced the incidence of stroke at 20 weeks of age. Candesartan also enhanced
the expression of adiponectin and leptin by inducing the overexpression of peroxisome proliferator activated
receptor γ. Circulating level of leptin was significantly higher in candesartan group than in the control group,
whereas adiponectin was similar in both groups. Intravenous administration of adiponectin resulted in
enhancement of adiponectin expression in adipose tissue, but no remarkable effects were found in
pathophysiology in SHRSP.
Conclusions: Our results indicate that candesartan protects against hypertension and adipocyte dysfunction in
SHRSP. The induction of leptin expression appeared to be important factor in the inhibition of stroke lesions,
whereas adiponectin was not a major regulator of blood pressure in SHRSP with genetic hypertension. Further
studies are needed to elucidate the role of the renin–angiotensin system in adipose tissue dysfunction in relation
to hypertensive end-organ damage.
Keywords: Stroke-prone spontaneously hypertensive rats, Adipose tissue, Renin–angiotensin system, Angiotensin II
type I receptor blocker, Lipoatrophy, AdipokinesBackground
As is well known, adipose tissue is a major endocrine
system, and the abnormal expression of adipokines by
hypertrophied adipocytes in obesity is involved in the
pathogenesis of hypertension and vascular disorders [1].
On the other hand, an association between hypertension* Correspondence: kuriman@nara.kindai.ac.jp
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reproduction in any medium, provided the orand lipoatrophy was also reported in patients infected
with human immunodeficiency virus [2,3] and in patients
with familiar partial lipodystrophy (FPLD3) [3,4].
Stroke-prone spontaneously hypertensive rats (SHRSP), a
well-established model of genetic hypertension, are lean
and develop marked lipoatrophy with the progress of
hypertension. Although several factors are involved in the
pathogenesis of severe hypertension in SHRSP, lipoatrophy
may be an important factor, because feeding these rats
a high-fat high-cholesterol diet improved lipoatrophy,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of stroke (unpublished data). These results suggest that
adipocyte dysfunction is related to hypertension in
SHRSP. Moreover, A-ZIP/F-1 mice, an animal model
of lipoatrophic diabetes, lack white adipose tissue and
exhibit hypertension [5]. We previously reported that
A-ZIP/F1 mice show higher blood pressure and enhanced
agonist-induced arterial wall contractility compared with
wild-type mice [6]. These findings suggest that adipose
tissue may have an important role in the pathogenesis
of hypertension in obesity and in lipoatrophy.
Since Engeli et al. [7] first reported that the renin-
angiotensin system (RAS) is localized in many tissues,
including adipose tissue, many studies have been performed
to examine the role of the RAS in adipose tissue in relation
to adipocyte differentiation and hypertension. For example,
Zorad et al. [8] investigated the effects of candesartan,
an angiotensin II type I receptor blocker (ARB), on adi-
pose tissue growth, and adipokine expression and release
in normotensive non-obese Wistar–Kyoto rats (WKY).
They reported that candesartan induced adipose tissue
hypotrophy and increased the expression of adiponectin
and peroxisome proliferator-activated receptor (PPAR)γ.
We previously reported that early and transient treatment
of SHRSP with low doses of candesartan prevented hyper-
tensive end-organ damage [9,10]. The protective effects of
ARBs against hypertension and its complications were
clearly demonstrated in a comprehensive series of studies
performed by Saavedra et al. [11-13]. Their and our findings
suggest that these beneficial effects of ARB may be due to
prolonged inhibition of the RAS in several tissues, includ-
ing adipose tissue. However, the mechanisms involved in
these effects of RAS inhibition were unclear.
In this study, we focused on the pathophysiological
characteristics of visceral adipose tissue in SHRSP. As
one of the beneficial effects of candesartan, we hypoth-
esized that candesartan may improve circulatory distur-
bances in SHRSP by enhancing adiponectin production as
a result of inhibiting the RAS in adipose tissue. To test this
hypothesis, we treated SHRSP with either candesartan or
adiponectin and determined the changes in blood pressure
and adipocyte function.
Results
Comparison of adipocyte function between WKY and SHRSP
We first assessed the adipokine expression profiles in
WKY and SHRSP at 6 and 20 weeks of age. Table 1 shows
the serum adipokine levels and mRNA expression in epi-
didymal adipose tissue. At 6 weeks of age, the serum leptin
and adiponectin levels were significantly lower in SHRSP
than in WKY. Furthermore, the mRNA expression levels of
leptin, adiponectin, and PPARγ were lower in SHRSP, con-
sistent with the circulating levels. The circulating leptin and
adiponectin levels were also lower in SHRSP than in WKYat 20 weeks of age. Although the mRNA expression level of
leptin in epididymal fat tissue was significantly lower in
SHRSP than in WKY, there were no significant differences
in either adiponectin or PPARγ mRNA expression levels
between WKY and SHRSP. These results indicate that
adipocyte dysfunction occurred before the onset of
hypertension in SHRSP. Based on these findings, we
conducted experiments to examine the effects of treating
SHRSP with an ARB.
Effects of candesartan on blood pressure, body weight,
and cerebral lesions
Table 2 presents the biological characteristics of 20-week-
old SHRSP treated with or without candesartan. Blood
pressure was significantly lower and body weight was
significantly heavier in the candesartan-treated group
than in the control group. The total visceral fat pad
weight was significantly greater in the candesartan-
treated group than in the control group. By contrast,
brain weight was significantly lower in the candesartan-
treated group than in the control group. Cerebral lesions
(edema, softening, or hemorrhage) were found in 7/8
rats (87.5%) in the control group but in none in the
candesartan-treated group.
Effects of candesartan on adipokine expression
As shown in Figure 1, plasma leptin levels were significantly
higher in the candesartan group than in the control group,
whereas serum adiponectin levels were similar in both
groups. However, the mRNA expression levels of leptin,
adiponectin, and PPARγ in adipocytes were significantly
greater in the candesartan group than in the control group,
as indicated in Table 3.
Effects of intravenous adiponectin administration
Table 4 shows the effects of continuous intravenous
infusion of adiponectin in SHRSP. There were no sig-
nificant differences in blood pressure or body weight
between the adiponectin-treated group and the con-
trol group. Blood adiponectin levels were slightly, but
not significantly, higher in the adiponectin-treated
group than in the control group, whereas leptin levels
were similar in both groups. The mRNA expression
level of adiponectin in adipose tissue was significantly
higher in the adiponectin-treated group than in the
control group. However, the expression levels of adiponectin
receptors (Adipo-R1, Adipo-R2, and cadherin 13) in
skeletal muscle were not significantly different between
the two groups.
Discussion
In the present study, we revealed that candesartan
ameliorated not only hypertension but also lipoatrophy
in SHRSP. One of the mechanisms of decreasing of
Table 1 Circulating and mRNA expression levels of adipocyte-related molecules in WKY and SHRSP
6 weeks of age 20 weeks of age
WKY SHRSP WKY SHRSP
Serum adipokine levels
Leptin (ng/ml) 2.895±0.700 0.568±0.450 9.003±0.673 4.497±0.383**
Adiponectin (μg/ml) 11.559±1.037 8.491±0.243** 10.054±0.219 5.934±0.222**
Adipokine expression in epididymal adipocytes (ratio to 18S rRNA)
Leptin 1.059±0.098 0.251±0.049** 4.204±0.746 2.012±0.177**
Adiponectin 1.045±0.070 0.609±0.050* 1.301±0.108 1.167±0.05
PPARγ 1.010±0.086 0.544±0.068* 0.517±0.038 0.407±0.050
SHRSP: stroke-prone spontaneously hypertensive rats; PPARγ: peroxisome proliferator-activated receptor γ; WKY: Wistar–Kyoto rats. Values are means ± SE.
*p < 0.05 and **p < 0.01 vs. age matched WKY (Student’s t-test).
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due to improvement of adipocyte dysfunction.
Although angiotensin II was reported to inhibit adipo-
cyte differentiation [14,15], angiotensin II-induced lipolysis
was ameliorated by the ARB losartan [16]. The angiotensin
II type 1 and type 2 receptors are involved in determining
adipocyte size [8,17]. Thus, the RAS in adipose tissue
is closely related to adipocyte growth and function.
Accordingly, angiotensin II signaling via the type 1 and
type 2 receptors may regulate adipocyte particle size,
and ARBs may ameliorate adipocyte dysfunction.
In this study, plasma leptin levels were higher in the
candesartan group than in the control group, but
adiponectin levels were similar in both groups. However,
the mRNA expression levels of leptin, adiponectin, and
PPARγ were higher in the candesartan group than in the
control group.
Leptin is secreted from hypertrophic adipocytes and
its circulating level is directly proportional to body fat.
In terms of its roles, leptin stimulates energy consumption
by activating the sympathetic nerve system and promotes
fatty acid β-oxidation in peripheral tissues [18]. Plasma
leptin and epididymal leptin mRNA levels were higher in
the candesartan group than in the control group. This
increase in leptin expression possibly contributed to
the lower incidence of stroke in the candesartan-treated
group. Although precise mechanisms are still unknown,







Blood pressure (mmhg) 265±5 213±6 <0.01*
Body weight (g) 287±8 307±6 <0.05*
Brain weight (g) 2.061±0.052 1.897±0.023 <0.05*
Stroke (rats with stroke/total rats) 7/8 (87.5%) 0/8 (0%) <0.01#
Total fat pad (g) 6.242±0.563 9.344±0.338 <0.05*
Values are means ± SE. *Student’s t-test; #Wilcoxon’s test.lopatrophy in SHRSP. This possibility is supported by a
study conducted by Avraham et al. [19], who reported that
leptin administration significantly improved neurological
disability and reduced infarct volume following permanent
middle cerebral artery occlusion in Sebra mice. Fur-
thermore, in clinical trials, it was reported that leptin
improved insulin resistance in lipoatrophic patients
[20,21]. Although further large-scale trials are needed
to demonstrate the long-term efficacy and safety of
leptin, a new drug application for leptin is anticipated
[22]. To explore the therapeutic role of leptin, Ebihara
et al. [23] crossed A-ZIP/F1 mice, which exhibit severe
lipoatrophy, with mice overexpressing leptin in the liver.
The resulting doubly transgenic mice virtually lacked
adipose tissue but had elevated leptin levels. These mice
showed improvements in insulin sensitivity, hepatic
steatosis, and normal glucose and insulin levels [23].
These results indicate that leptin has an important role
in the pathogenesis of circulatory disturbance as well as
metabolic disorders.
On the other hand, the mRNA expression levels of
adiponectin and PPARγ were also increased in the
candesartan-treated group. PPARγ is nuclear transcription
factor in adipocytes, where it control the expression of nu-
merous genes involved in glucose and lipid metabolism,
and cell differentiation in particular [24]. Zorad et al. [8]
investigated the effects of candesartan in normotensive
WKY and reported marked decreases in body weight with
increasing of expression of adiponectin and PPARγ. How-
ever, the plasma leptin level and its mRNA expression in
adipose tissue were lower in the candesartan group than
in the control group. Their findings were generally similar
to those of our present study, except for leptin expression.
This difference may be due to differences in methods, in-
cluding strain of rat, candesartan dose, and the duration
of treatment. Nevertheless, the results of both studies are
consistent in terms of the improvement in adipocyte func-
tion in candesartan-treated rats.
As described above, candesartan ameliorated adipocyte
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Figure 1 Effects of candesartan on plasma leptin and serum adiponectin levels. Values are means ± SE. *p < 0.05 vs. the control group.







Blood pressure (mmHg) 241±3 249±7 ns
Body weight (g) 305±7 303±8 ns
Blood
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hypothesis, we investigated the effects of continuous intra-
venous infusion of recombinant adiponectin in mature
SHRSP. The results of this experiment revealed an increase
in plasma adiponectin levels, although the increase was not
statistically significant. However, the adiponectin mRNA
expression level in adipose tissue was significantly higher in
the adiponectin-treated group than in the control group.
On the other hand, there were no significant differences in
the mRNA expression levels of leptin, Adipo-R1, AdipoR-2,
or cadherin 13 between the two groups. Unexpectedly, we
found no differences in body weight or blood pressure
between the two groups. Bassi et al. [25] investigated the
chronic effects of centrally administered adiponectin in
SHR and reported that adiponectin did not appear to have
an important role in long-term control of blood pressure.
Thus, we and Bassi et al. [25] found no remarkable
effects of adiponectin on the circulatory disturbances in
SHR or SHRSP. This means that adiponectin is not a
major regulator of blood pressure in essential (i.e., genetic)
hypertension. However, several reports have indicated that
adiponectin may lower blood pressure by regulating the
nitric oxide synthetic pathway [26,27]. We did not investi-
gate the changes in nitric oxide-related molecules in the
present study.
In conclusion, we revealed the candesartan has benefi-
cial effects not only for decreasing of blood pressure but
also improvement of adipocyte dysfunction, although theTable 3 Effects of candesartan on mRNA expression levels
of adipocyte-related molecules
Control group Candesartan group p*
Leptin 0.17±0.02 0.36±0.05 <0.01
Adiponectin 0.53±0.06 0.94±0.11 <0.01
PPARγ 0.11±0.02 0.34±0.07 <0.01
PPARγ: peroxisome proliferator-activated receptor γ. Expression levels are
shown as the ratio to 18S rRNA. Values are means ± SE. *Student’s t-test.latter must be secondary to decreasing of blood pressure.
Leptin may be more deeply related to decreasing of stroke
as compared to adiponectin in SHRSP. Further studies are
required to elucidate t role of renin-angiotensin system in
adipocyte in relation to hypertension and stroke.Materials and methods
Animals
Male SHRSP/kpo and Wistar–Kyoto rats (WKY/kpo), as a
normotensive control, were used in this study. These rats
are from the original strains provided by Dr. Okamoto
(Kyoto University) and were maintained at the Animal
Center, Faculty of Medicine, Kinki University. All ex-
perimental protocols conformed to the guidelines of the
National Institutes of Health (Guide for the Care and
Use of Laboratory Animals 1996), and were approved by
the Institutional Animal Experimentation Committee of
Kinki University.Adiponectin (ng/ml) 7160±680 7974±388 ns
Leptin (pg/ml) 2593±807 2331±363 ns
Adipose tissue
Adiponectin Ratio to 18SrRNA 0.23±0.02 0.51±0.06 <0.01
Muscle
Adipo-R1 Ratio to 18SrRNA 0.97±014 0.95±0.06 ns
Adipo-R2 0.99±0.13 0.76±0.09 ns
Cadherin 13 22.29±3.89 16.72±1.35 ns
Adipo-R: adiponectin receptor. Values are means ± SE. *Student’s t-test.
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Male SHRSP and WKY were used at 6 and 20 weeks of age
(6 rats in each). The biological factors (as described below),
serum adipokine levels, and the mRNA expression levels
of adipocyte-related genes in epididymal fat tissue were
determined.
Effects of candesartan administration
Male SHRSP at 15 weeks of age were randomly divided
into a control group and a candesartan-treated group
(eight rats per group). Candesartan (Takeda Pharmaceutical
Co. Ltd., Tokyo, Japan) was orally administered for 5 weeks
from 16 weeks of age (2 mg/kg/day).
Effects of adiponectin administration
To investigate the effects of exogenous adiponectin on the
pathophysiology in SHRSP, we first cloned rat adiponectin
using Escherichia coli, as described below. Purified
adiponectin (in phosphate-buffered saline [PBS]) was ad-
ministered to five 16-week-old SHRSP for 2 weeks using an
osmotic mini-pump (100 μg/day). Control rats (n = 5) were
administered PBS alone (n = 5).
Measurements
Blood pressure and body weight was measured once
weekly until 20 weeks of age. Blood pressure was
measured using the tail-cuff method in conscious rats. At
20 weeks of age, blood samples were taken from the vena
cava under sodium pentobarbital anesthesia. Plasma
samples were prepared from blood collected in heparinized
syringes by centrifugation at 6,000 × g for 10 min.
Serum samples were prepared from blood collected in
non-heparinized syringes by centrifugation at 10,000 × g
for 10 min. Brain and epididymal fat tissue were excised,
weighed, and observed macroscopically.
Molecular cloning, expression, and purification of full-length
rat adiponectin
The adiponectin gene (Adipoq, NM_144744) was amp-
lified from cDNA prepared using the reverse primer 5’-
ACCCAAGCTTCAGTTGGTATCATGGTAG-3’. The
resulting PCR product was digested with BamHI and
HindIII, and then cloned into a pQE30 vector (Qiagen,
Hilden, Germany), which has 6× His tag at the N
terminus the adiponectin gene. The construct was then
transformed into E. coli JM109 (New England BioLabs,
Ipswich, MA, USA) and screened on Luria broth medium
containing 100 μg/ml ampicillin (LB-Amp). The plasmid
was collected from LB-Amp–screened E. coli JM109 and
the Adipoq sequence was screened using an ABI PRISM®
310 Genetic Analyzer (Applied BioSystems, Foster City,
CA, USA).
E. coli JM109 containing the Adipoq gene were culti-
vated in LB-Amp at 37°C by inducing adiponectin proteinexpression with isopropyl-β-D-thiogalactopyranoside. The
bacteria were harvested and stored at −20°C until use. The
E. coli were then solubilized with lysis buffer containing
BugBuster (Takara Bio, Shiga, Japan), 100 mM imidazole,
and protease inhibitor cocktail (Sigma, St. Louis, MO, USA)
in PBS (pH 7.4) at room temperature for 30 min, followed
by centrifugation at 16,000 × g for 20 min. The precipitates
were collected because adiponectin protein was stored in
inclusion body (data not shown). The inclusion bodies
were isolated using BugBuster, and then solubilized and
denatured with 2 ml of PBS (pH 7.4) containing 7 M
guanidine-HCl and 1% (v/v) α-mercaptoethanol at room
temperature. The denatured adiponectin was refolded
by incubation in a 200-fold volume of PBS containing
2 M urea at 4°C for 3 days. After concentration, the
adiponectin was purified using an Ni Sepharose™ 6 Fast
Flow column (GE Healthcare, Little Chalfont, UK) by
eluting with PBS containing 200 mM imidazole. The
purified adiponectin was cleared of endotoxin using
ActiClean Etox (Sterogene Bioseparations Inc., Carlsbad,
CA, USA), concentrated, transferred to PBS, and passed
through a 0.22 μm filter.Analysis of adipokine levels
Plasma leptin and serum adiponectin levels were mea-
sured using commercial enzyme-linked immunosorbent
assays (B-Bridge International Inc., Cupertino, CA, USA;
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). The
optical density of each sample was measured using a Bio
Rad model 680 spectrophotometer (Bio-Rad Laboratories,
Hercules, CA, USA).
The mRNA expression levels of leptin, adiponectin,
and PPARγ in epididymal adipose tissue were analyzed
by real-time polymerase chain reaction (RT-PCR). The
expression levels of Adipo-R1, Adipo-R2, and cadherin
13 in skeletal muscle were also determined by RT-PCR.
Briefly, total RNA was isolated using an RNeasy Mini
Kit (Qiagen) and cDNA was synthesized using an ExScript
RT reagent kit (Takara Bio). RT-PCR was performed using
the SYBR Premix Ex Taq (Takara Bio) on an ABI 9700HT
(Applied Biosystems) with PCR primers purchased from
Takara Bio.Statistical analysis
Statistical analysis was carried out using Student’s t-test
for blood pressure and biochemical factors. Wilcoxon’s
test was used for the incidence of stroke.
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